Scalable and Eco-friendly Bioproductionbroad
SEB · Horizon Europe grant · 2023-01-01–2024-12-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2022-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2022-ACCELERATOROPEN-01. CORDIS record →
Objective
Core Biogenesis uses plant-based expression systems for the very large-scale and high-quality bioproduction of pharmaceutical-grade recombinant proteins. The latter are used as growth factors (GF) in synthetic cell culture media for clinical and commercial scale biomanufacturing of cell therapy. The company has developed a novel advanced proprietary bioprocess integrating breakthrough innovations overcoming major technical issues of plant systems by offering a 25-fold yield increase and a 10-fold cost reduction. Its biomanufacturing platform will enable Core Biogenesis to fully exploit the great potential of plants for large and scalable production capacity as plants are well known to be the most promising system for production upscaling. Core Biogenesiss ambition is to position itself as the European leader in plant-based biomanufacturing by 2025.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| CORE BIOGENESIS | FR | coordinator | €1,153,390 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.